Dare Bioscience, Inc. (DARE) - Dilution Analysis

8-K filing: Daré Bioscience, Inc. completed the issuance of 50,000 units, each containing one share of Series A Convertible Preferred Stock and two warrants to purchase common stock, for a total offering price of $5.00 per unit. ($0.25M proceeds)

10-Q filing | 14.5M shares outstanding

8-K filing: Daré Bioscience, Inc. completed closings of its Regulation A offering of 195,010 units, with each unit consisting of one share of Series A Convertible Preferred Stock and two warrants, each to purchase one share of common stock, at a price of $5.00 per unit. ($0.98M proceeds)

8-K filing: Daré Bioscience, Inc. completed a Regulation A offering of 20,000 units, with each unit consisting of one share of Series A Convertible Preferred Stock and warrants to purchase two shares of common stock, at a price of $5.00 per unit. ($0.1M proceeds)

8-K filing: Daré Bioscience, Inc. completed a Regulation A offering of 3,470 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase one share of common stock, at an offering price of $5.00 per unit on April 10, 2026. ($0.02M proceeds)

10-K filing | 14.6M shares outstanding

8-K filing: Daré Bioscience, Inc. completed a Regulation A offering of 43,050 units, with each unit consisting of one share of Series A Convertible Preferred Stock and two warrants, each to purchase one share of common stock, at a price of $5.00 per unit. ($0.22M proceeds)

8-K filing: Daré Bioscience, Inc. completed the second closing of its Regulation A offering, issuing 17,500 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and Investor Warrants to purchase up to 35,000 shares of common stock, at an offering price of $5.00 per unit. ($0.09M proceeds)

8-K filing: Daré Bioscience completed the initial closing of a Regulation A offering, issuing 5,090 units, each consisting of one share of Series A Preferred Stock and two warrants, at a price of $5.00 per unit. ($0.03M proceeds)

10-Q filing | 14.3M shares outstanding

10-Q filing | 13.5M shares outstanding

10-Q filing | 8.8M shares outstanding

10-K filing | 8.5M shares outstanding

S-1 filing: This prospectus relates to the resale of common stock by Lincoln Park Capital Fund, LLC, with the company potentially receiving up to $15,000,000 in gross proceeds from sales to Lincoln Park under a purchase agreement.

10-Q filing | 8.5M shares outstanding

8-K filing: Daré Bioscience, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $15.0 million in shares of its common stock and issued 137,614 shares to Lincoln Park in consideration for its commitment.

10-Q filing | 8.5M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 100,514,272 → 8,400,000

10-Q filing | 100.5M shares outstanding

S-3 filing: This is an S-3 filing for a shelf offering of up to 15,000,000 shares of common stock by selling stockholders.

S-3 filing: Daré Bioscience, Inc. may offer shares of its common stock and preferred stock, various series of debt securities and/or warrants, rights or purchase contracts to purchase any of such securities, either individually or in units, with a total value of up to $200,000,000.

10-K filing | 100.6M shares outstanding

8-K filing: Dare Bioscience entered into a Royalty Interest Financing Agreement with United in Endeavour, LLC, selling the right to receive certain royalty payments for up to $12 million, and issued warrants to United to purchase up to 12,000,000 shares of common stock at an exercise price of $0.3467 per share.

10-Q filing | 91.1M shares outstanding

8-K filing: Daré Bioscience, Inc. entered into a securities purchase agreement for a registered direct offering of 10,000,000 shares of common stock and warrants to purchase 10,000,000 shares at a price of $0.70 per share and warrant, with gross proceeds expected to be $7.0 million. ($7.0M proceeds)

10-Q filing | 86.4M shares outstanding

10-Q filing | 85.5M shares outstanding

10-K filing | 84.6M shares outstanding

10-Q filing | 84.8M shares outstanding

10-Q filing | 84.7M shares outstanding

10-Q filing | 83.9M shares outstanding

10-K filing | 83.9M shares outstanding

10-Q filing | 70.8M shares outstanding

10-Q filing | 70.5M shares outstanding

10-Q filing | 49.4M shares outstanding

10-K filing | 47.3M shares outstanding

S-3 filing: Registration of common stock, preferred stock, debt securities, warrants, rights and purchase contracts with an aggregate initial offering price not to exceed $200,000,000, including unsold securities from a previous registration.

S-1/A filing: This S-1/A filing details an equity line of credit with Lincoln Park where the company may sell up to $15.0 million of common stock, with approximately $7.0 million remaining available under the agreement as of the filing date.

S-1/A filing: This S-1/A filing relates to a purchase agreement with Lincoln Park, where Lincoln Park agreed to purchase up to $15.0 million of common stock. As of the prospectus date, $7.4 million of common stock has been purchased. The company may sell up to 19.99% of shares of common stock outstanding immediately prior to the execution of the Purchase Agreement.

S-1 filing: This S-1 filing describes a purchase agreement with Lincoln Park, where Lincoln Park agreed to purchase from the company up to an aggregate of $15.0 million of common stock and issuance of Commitment Shares.

10-Q filing | 38.0M shares outstanding

10-Q filing | 31.6M shares outstanding

S-3 filing: This is an S-3 filing for the registration of 5,008,917 shares of common stock for resale by selling stockholders, acquired in connection with the acquisition of Microchips Biotech, Inc.

10-Q filing | 26.6M shares outstanding

S-1 filing: This S-1 filing registers for resale 7,500,000 shares of common stock by Lincoln Park Capital Fund, LLC, the selling stockholder, pursuant to a purchase agreement for up to $15,000,000 of common stock.

10-K filing | 24.7M shares outstanding

8-K filing: Daré Bioscience, Inc. reports regaining compliance with Nasdaq Listing Rule 5550(b) due to completed transactions in November 2019 and January 2020, including the acquisition of Microchips Biotech, Inc. and the sale of common stock and exercise of warrants. ($6.8M proceeds)